CN100457781C - 抗癌抗体 - Google Patents

抗癌抗体 Download PDF

Info

Publication number
CN100457781C
CN100457781C CNB028073177A CN02807317A CN100457781C CN 100457781 C CN100457781 C CN 100457781C CN B028073177 A CNB028073177 A CN B028073177A CN 02807317 A CN02807317 A CN 02807317A CN 100457781 C CN100457781 C CN 100457781C
Authority
CN
China
Prior art keywords
cancer
cripto
mab
cells
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB028073177A
Other languages
English (en)
Chinese (zh)
Other versions
CN1639194A (zh
Inventor
伊恩·法奎尔·坎贝尔·麦肯奇
邢培祥
胡秀凤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Macfarlane Burnett Institute For Medical Research And Public Health Ltd
Original Assignee
Macfarlane Burnet Institute for Medical Research and Public Health Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macfarlane Burnet Institute for Medical Research and Public Health Ltd filed Critical Macfarlane Burnet Institute for Medical Research and Public Health Ltd
Publication of CN1639194A publication Critical patent/CN1639194A/zh
Application granted granted Critical
Publication of CN100457781C publication Critical patent/CN100457781C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNB028073177A 2001-03-26 2002-03-26 抗癌抗体 Expired - Fee Related CN100457781C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPR3958A AUPR395801A0 (en) 2001-03-26 2001-03-26 Antibodies against cancer
AUPR3958 2001-03-26

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNA2008101103851A Division CN101310770A (zh) 2001-03-26 2002-03-26 抗癌抗体

Publications (2)

Publication Number Publication Date
CN1639194A CN1639194A (zh) 2005-07-13
CN100457781C true CN100457781C (zh) 2009-02-04

Family

ID=3827964

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB028073177A Expired - Fee Related CN100457781C (zh) 2001-03-26 2002-03-26 抗癌抗体
CNA2008101103851A Pending CN101310770A (zh) 2001-03-26 2002-03-26 抗癌抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA2008101103851A Pending CN101310770A (zh) 2001-03-26 2002-03-26 抗癌抗体

Country Status (9)

Country Link
US (1) US7318924B2 (enExample)
EP (1) EP1383801A4 (enExample)
JP (2) JP4854912B2 (enExample)
KR (1) KR100909290B1 (enExample)
CN (2) CN100457781C (enExample)
AU (3) AUPR395801A0 (enExample)
CA (1) CA2442318A1 (enExample)
NZ (1) NZ528624A (enExample)
WO (1) WO2002077033A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0020953D0 (en) 2000-08-24 2000-10-11 Smithkline Beecham Biolog Vaccine
US7582299B2 (en) 2001-04-26 2009-09-01 Biogen Idec Ma Inc. Cripto-specific antibodies
RS20110024A (sr) 2001-04-26 2011-08-31 Biogen Idec Ma Inc. Antitela koja blokiraju cripto i njihova upotreba
AU2003301619A1 (en) * 2002-10-23 2004-05-13 Exelixis, Inc. MBMs AS MODIFIERS OF BRANCHING MORPHOGENESIS AND METHODS OF USE
US7824872B2 (en) 2003-04-03 2010-11-02 Theravalues Corporation Pharmaceutical agents
US20050163782A1 (en) * 2003-06-27 2005-07-28 Biogen Idec Ma Inc. Modified binding molecules comprising connecting peptides
AU2004274433B2 (en) * 2003-09-15 2010-08-12 Research Development Foundation Cripto antagonism of activin and TGF-beta signaling
WO2005037293A1 (en) 2003-10-16 2005-04-28 Univ Monash Immunomodulating compositions and uses therefor
EP2311881A3 (en) * 2005-01-05 2011-07-27 Biogen Idec MA Inc. Cripto binding molecules
US7939056B2 (en) * 2005-11-14 2011-05-10 The Brigham And Women's Hospital, Inc. Interleukin-10 compositions for the treatment of adenocarcinomas
CA2688563A1 (en) * 2007-06-01 2008-12-11 Biogen Idec Ma Inc. Cripto binding molecules
EP3156069B8 (en) 2008-06-20 2020-10-21 Duke University Compositions, methods, and kits for eliciting an immune response
KR100973029B1 (ko) * 2008-10-07 2010-08-11 박지운 알루미늄 합금 가로등 등주
EP2350131B1 (en) * 2008-11-07 2017-06-07 Research Development Foundation Compositions and methods for the inhibition of cripto/grp78 complex formation and signaling
WO2012105219A1 (ja) * 2011-01-31 2012-08-09 オリンパス株式会社 抗体療法の効果増強剤
KR102023496B1 (ko) 2011-04-21 2019-09-20 시애틀 지네틱스, 인크. 신규 결합제-약물 콘주게이트 (adc) 및 그의 용도
MX380273B (es) 2013-12-23 2025-04-01 Bayer Pharma AG Conjugados de farmacos anticuerpo (adcs) con inhibidores de ksp.
US11198738B2 (en) * 2015-04-20 2021-12-14 Minomic International Ltd. Therapeutic antibodies and uses thereof
SG10201908685QA (en) 2015-06-22 2019-10-30 Bayer Pharma AG Antibody drug conjugates (adcs) and antibody prodrug conjugates (apdcs) with enzymatically cleavable groups
EP3313523A2 (en) 2015-06-23 2018-05-02 Bayer Pharma Aktiengesellschaft Targeted conjugates of ksp inhibitors
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
JP7251981B2 (ja) 2016-03-24 2023-04-04 バイエル ファーマ アクチエンゲゼルシャフト 酵素開裂基を有する細胞毒性活性剤のプロドラッグ
CA3027445A1 (en) 2016-06-15 2017-12-21 Bayer Pharma Aktiengesellschaft Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies
CA3047522A1 (en) 2016-12-21 2018-06-28 Bayer Pharma Aktiengesellschaft Specific antibody drug conjugates (adcs) having ksp inhibitors
EP3558386A1 (de) 2016-12-21 2019-10-30 Bayer Aktiengesellschaft Prodrugs von cytotoxischen wirkstoffen mit enzymatisch spaltbaren gruppen
JP7066714B2 (ja) 2016-12-21 2022-05-13 バイエル・ファルマ・アクティエンゲゼルシャフト 酵素的に切断可能な基を有する抗体薬物コンジュゲート（ａｄｃ）
CN109744199A (zh) * 2017-11-08 2019-05-14 南京艾莫瑞生物科技有限公司 一种肿瘤细胞异种移植斑马鱼模型、其构建方法及应用
JP6761889B1 (ja) * 2019-11-11 2020-09-30 株式会社Ｇｓｐエンタープライズ 抗ヒトＣｒｉｐｔｏ−１抗体

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1332745A (zh) * 1999-03-11 2002-01-23 阿登尼亚投资有限公司 治疗癌症的新化合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5171665A (en) * 1989-04-17 1992-12-15 Oncogen Monoclonal antibody to novel antigen associated with human tumors
US5256643A (en) * 1990-05-29 1993-10-26 The Government Of The United States Human cripto protein
US5264557A (en) * 1991-08-23 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Polypeptide of a human cripto-related gene, CR-3
US5981215A (en) * 1995-06-06 1999-11-09 Human Genome Sciences, Inc. Human criptin growth factor
ES2312177T3 (es) * 1996-05-22 2009-02-16 Viventia Biotech Inc. Fragmentos de union a antigenos que detectan especificamente celulas cancerosas, nucleotidos que codifican los fragmentos y el uso de los mismos para la profilaxis y deteccion de canceres.
IL125608A0 (en) * 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines
US6333410B1 (en) * 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
GB0020953D0 (en) * 2000-08-24 2000-10-11 Smithkline Beecham Biolog Vaccine
AU2001292724B2 (en) * 2000-09-18 2005-05-26 Biogen Idec Ma Inc. CRIPTO mutant and uses thereof
US7582299B2 (en) * 2001-04-26 2009-09-01 Biogen Idec Ma Inc. Cripto-specific antibodies
RS20110024A (sr) 2001-04-26 2011-08-31 Biogen Idec Ma Inc. Antitela koja blokiraju cripto i njihova upotreba

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1332745A (zh) * 1999-03-11 2002-01-23 阿登尼亚投资有限公司 治疗癌症的新化合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Cooperative inhibiton of renal cancer growth byanti-epidermal growth factor receptor antibody and proteinkinase A antisense oligonucleotide. Fortunato Ciardiello et al.Journal of the National Cancer Institute,Vol.90 No.14. 1998 *
Inhibition of Cripto expression and tumorigenicity inhumancolon cancer cells by antisense RNAandoligodeoxynucleotides. Fortunato Ciardiello et al.Oncogene,Vol.9. 1994 *

Also Published As

Publication number Publication date
KR20040010613A (ko) 2004-01-31
US7318924B2 (en) 2008-01-15
WO2002077033A1 (en) 2002-10-03
AU2007201587A1 (en) 2007-05-03
US20040176576A1 (en) 2004-09-09
EP1383801A1 (en) 2004-01-28
CN101310770A (zh) 2008-11-26
JP2004534741A (ja) 2004-11-18
AU2002240719B2 (en) 2007-01-11
EP1383801A4 (en) 2005-06-01
AUPR395801A0 (en) 2001-04-26
CA2442318A1 (en) 2002-10-03
JP4854912B2 (ja) 2012-01-18
CN1639194A (zh) 2005-07-13
NZ528624A (en) 2006-03-31
JP2009024014A (ja) 2009-02-05
KR100909290B1 (ko) 2009-07-24

Similar Documents

Publication Publication Date Title
CN100457781C (zh) 抗癌抗体
JP6728264B2 (ja) 抗ｈｅｒ２抗体及びその結合体
AU2002240719A1 (en) Antibodies against cancer
KR102134088B1 (ko) Ror1 암을 치료하고 전이를 저해하는데 이용을 위한 항체와 백신
CN101155830B (zh) 结合epha2的抗体及其使用方法
CN110869394A (zh) 工程改造的抗体化合物及其缀合物
JP2005508839A (ja) ペプチドおよびｍｕｃ１タンパク質に対する抗体
CN116615250A (zh) 通过施用抗b7-h3抗体-药物缀合物的间皮瘤治疗
CN110382532A (zh) 抗g-csf抗体及其用途
WO2022048521A1 (zh) 抗c-Met抗体药物偶联物及其应用
KR20010101446A (ko) 항암 예방접종용 항체의 용도
CN111848805A (zh) 用于肿瘤免疫治疗的具有双Her2位点的双特异性抗体
CN111051342B (zh) 抗硫酸化糖胺聚糖抗体
WO2022029591A1 (en) Treatment with site specific her2 antibody-drug conjugates
ES2348161T3 (es) Métodos para dañar células usando funciones efectoras de anticuerpos anti-gfra1.
US20100119514A1 (en) Antibodies Against Cancer
US20230061858A1 (en) Treatment with site specific her2 antibody-drug conjugates
CN115884794A (zh) 抗her2抗体药物缀合物与her二聚化抑制剂的组合
CN116333143A (zh) Scube2中和抗体及其医药用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH +

Free format text: FORMER OWNER: AUSTIN RES INST

Effective date: 20120723

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20120723

Address after: Vitoria Australia

Patentee after: Macfarlane Burnett Institute for medical research and Public Health Limited

Address before: Vitoria Australia

Patentee before: Austin Res Inst

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20090204

Termination date: 20130326